{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T09:05:54Z","timestamp":1768467954886,"version":"3.49.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00393-024-01548-1","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T13:02:19Z","timestamp":1724850139000},"page":"787-799","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Therapie-Update der ANCA-assoziierten Vaskulitiden","Update on treatment of ANCA-associated vasculitis"],"prefix":"10.1007","volume":"83","author":[{"given":"Julia U.","family":"Holle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Moosig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"issue":"10","key":"1548_CR1","doi-asserted-by":"publisher","first-page":"4868","DOI":"10.1093\/rheumatology\/keaa924","volume":"60","author":"B Hellmich","year":"2021","unstructured":"Hellmich\u00a0B, Lamprecht\u00a0P, Spearpoint\u00a0P, Gotte\u00a0D, Deichmann\u00a0A, Buchholz\u00a0I et\u00a0al (2021) New insights into the epidemiology of ANCA-associated vasculitides in Germany: results from a\u00a0claims data study. Rheumatology 60(10):4868\u20134873","journal-title":"Rheumatology"},{"key":"1548_CR2","doi-asserted-by":"crossref","unstructured":"Hellmich B, Sanchez-Alamo B, Schirmer JH, Berti A, Blockmans D, Cid MC et\u00a0al (2023) EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis","DOI":"10.1136\/ard-2022-223764"},{"issue":"3S","key":"1548_CR3","first-page":"S71","volume":"105","author":"Kidney Disease","year":"2024","unstructured":"Kidney Disease (2024) KDIGO 2024 clinical practice guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis. Kidney Int 105(3S):S71\u2013S116","journal-title":"Kidney Int"},{"issue":"6","key":"1548_CR4","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1136\/ard.2009.109389","volume":"69","author":"MA Little","year":"2010","unstructured":"Little\u00a0MA, Nightingale\u00a0P, Verburgh\u00a0CA, Hauser\u00a0T, De Groot\u00a0K, Savage\u00a0C et\u00a0al (2010) Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 69(6):1036\u20131043","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1548_CR5","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1093\/ndt\/gfac320","volume":"38","author":"B Sanchez Alamo","year":"2023","unstructured":"Sanchez Alamo\u00a0B, Moi\u00a0L, Bajema\u00a0I, Faurschou\u00a0M, Flossmann\u00a0O, Hauser\u00a0T et\u00a0al (2023) Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis. Nephrol Dial Transplant 38(7):1655\u20131665","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"1548_CR6","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1002\/art.21142","volume":"52","author":"K De Groot","year":"2005","unstructured":"De Groot\u00a0K, Rasmussen\u00a0N, Bacon\u00a0PA, Tervaert\u00a0JW, Feighery\u00a0C, Gregorini\u00a0G et\u00a0al (2005) Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52(8):2461\u20132469","journal-title":"Arthritis Rheum"},{"issue":"3","key":"1548_CR7","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","volume":"78","author":"RB Jones","year":"2019","unstructured":"Jones\u00a0RB, Hiemstra\u00a0TF, Ballarin\u00a0J, Blockmans\u00a0DE, Brogan\u00a0P, Bruchfeld\u00a0A et\u00a0al (2019) Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a\u00a0randomised, non-inferiority trial. Ann Rheum Dis 78(3):399\u2013405","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1548_CR8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JHMP Stone","year":"2010","unstructured":"Stone\u00a0JHMP, Spiera\u00a0R, Seo\u00a0P, Langford\u00a0CA, Hoffman\u00a0GS, Kallenberg\u00a0CG, St Clair\u00a0EW, Turkiewicz\u00a0A, Tchao\u00a0NK, Webber\u00a0L, Ding\u00a0L, Sejismundo\u00a0LP, Mieras\u00a0K, Weitzenkamp\u00a0D, Ikle\u00a0D, Seyfert-Margolis\u00a0V, Mueller\u00a0M, Brunetta\u00a0P, Allen\u00a0NB, Fervenza\u00a0FC, Geetha\u00a0D, Keogh\u00a0KA, Kissin\u00a0EY, Monach\u00a0PA, Peikert\u00a0T, Stegeman\u00a0C, Ytterberg\u00a0SR, Specks\u00a0U (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N\u00a0Engl J Med 363(2):221\u2013232","journal-title":"N Engl J Med"},{"issue":"7","key":"1548_CR9","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne\u00a0DRW, Merkel\u00a0PA, Schall\u00a0TJ, Bekker\u00a0P, Group AS (2021) Avacopan for the treatment of ANCA-associated vasculitis. N\u00a0Engl J Med 384(7):599\u2013609","journal-title":"N Engl J Med"},{"issue":"3","key":"1548_CR10","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"JW Jones RBT","year":"2010","unstructured":"Jones RBT\u00a0JW, Hauser\u00a0T, Luqmani\u00a0R, Morgan\u00a0MD, Peh\u00a0CA, Savage\u00a0CO, Segelmark\u00a0M, Tesar\u00a0V, vsn Paassen\u00a0P, Walsh\u00a0D, Westman\u00a0K, Jayne\u00a0DR, European Vasculitis Study Group (2010) Rituxmab versus cyclophosphamide in ANCA-associated renal vasculitis. N\u00a0Engl J Med 363(3):211\u2013220","journal-title":"N Engl J Med"},{"issue":"9","key":"1548_CR11","doi-asserted-by":"publisher","first-page":"e061339","DOI":"10.1136\/bmjopen-2022-061339","volume":"12","author":"E Dirikgil","year":"2022","unstructured":"Dirikgil\u00a0E, van Leeuwen\u00a0JR, Bredewold\u00a0OW, Ray\u00a0A, Jonker\u00a0JT, Soonawala\u00a0D et\u00a0al (2022) ExploriNg durable remission with rituximab in ANCA-associatEd vasculitis (ENDURRANCE trial): protocol for a\u00a0randomised controlled trial. BML Open 12(9):e61339","journal-title":"BML Open"},{"issue":"6","key":"1548_CR12","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/qjmed\/90.6.401","volume":"90","author":"D Adu","year":"1997","unstructured":"Adu\u00a0D, Pall\u00a0A, Luqmani\u00a0RA, Richards\u00a0NT, Howie\u00a0AJ, Emery\u00a0P et\u00a0al (1997) Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM 90(6):401\u2013409","journal-title":"QJM"},{"issue":"12","key":"1548_CR13","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1002\/art.1780401213","volume":"40","author":"L Guillevin","year":"1997","unstructured":"Guillevin\u00a0L, Cordier\u00a0JF, Lhote\u00a0F, Cohen\u00a0P, Jarrousse\u00a0B, Royer\u00a0I et\u00a0al (1997) A\u00a0prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener\u2019s granulomatosis. Arthritis Rheum 40(12):2187\u20132198","journal-title":"Arthritis Rheum"},{"issue":"10","key":"1548_CR14","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1002\/1529-0131(199810)41:10<1835::AID-ART16>3.0.CO;2-Q","volume":"41","author":"M Haubitz","year":"1998","unstructured":"Haubitz\u00a0M, Schellong\u00a0S, Gobel\u00a0U, Schurek\u00a0HJ, Schaumann\u00a0D, Koch\u00a0KM et\u00a0al (1998) Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a\u00a0prospective, randomized study. Arthritis Rheum 41(10):1835\u20131844","journal-title":"Arthritis Rheum"},{"issue":"8","key":"1548_CR15","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1093\/rheumatology\/keac716","volume":"62","author":"MA Podesta","year":"2023","unstructured":"Podesta\u00a0MA, Mescia\u00a0F, Ricchiuto\u00a0A, Smith\u00a0R, Tedesco\u00a0M, Cassia\u00a0MA et\u00a0al (2023) Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a\u00a0rituximab-based induction: a\u00a0multicentre study. Rheumatology 62(8):2850\u20132854","journal-title":"Rheumatology"},{"issue":"5","key":"1548_CR16","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1136\/ard-2022-223401","volume":"82","author":"B Odler","year":"2023","unstructured":"Odler\u00a0B, Riedl\u00a0R, Gauckler\u00a0P, Shin\u00a0JI, Leierer\u00a0J, Merkel\u00a0PA et\u00a0al (2023) Risk factors for serious infections in ANCA-associated vasculitis. Ann Rheum Dis 82(5):681\u2013687","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1548_CR17","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1056\/NEJMoa1803537","volume":"382","author":"M Walsh","year":"2020","unstructured":"Walsh\u00a0M, Merkel\u00a0PA, Peh\u00a0CA, Szpirt\u00a0WM, Puechal\u00a0X, Fujimoto\u00a0S et\u00a0al (2020) Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N\u00a0Engl J Med 382(7):622\u2013631","journal-title":"N Engl J Med"},{"issue":"21","key":"1548_CR18","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1001\/jama.2021.6615","volume":"325","author":"S Furuta","year":"2021","unstructured":"Furuta\u00a0S, Nakagomi\u00a0D, Kobayashi\u00a0Y, Hiraguri\u00a0M, Sugiyama\u00a0T, Amano\u00a0K et\u00a0al (2021) Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a\u00a0randomized clinical trial. JAMA 325(21):2178\u20132187","journal-title":"JAMA"},{"issue":"4","key":"1548_CR19","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.ekir.2023.01.039","volume":"8","author":"FB Cortazar","year":"2023","unstructured":"Cortazar\u00a0FB, Niles\u00a0JL, Jayne\u00a0DRW, Merkel\u00a0PA, Bruchfeld\u00a0A, Yue\u00a0H et\u00a0al (2023) Renal recovery for patients with ANCA-associated vasculitis and low eGFR in the ADVOCATE trial of avacopan. Kidney Int Rep 8(4):860\u2013870","journal-title":"Kidney Int Rep"},{"key":"1548_CR20","doi-asserted-by":"publisher","first-page":"e064604","DOI":"10.1136\/bmj-2021-064604","volume":"376","author":"M Walsh","year":"2022","unstructured":"Walsh\u00a0M, Collister\u00a0D, Zeng\u00a0L, Merkel\u00a0PA, Pusey\u00a0CD, Guyatt\u00a0G et\u00a0al (2022) The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis. BMJ 376:e64604","journal-title":"BMJ"},{"issue":"6","key":"1548_CR21","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1002\/art.39562","volume":"68","author":"R Cartin-Ceba","year":"2016","unstructured":"Cartin-Ceba\u00a0R, Diaz-Caballero\u00a0L, Al-Qadi\u00a0MO, Tryfon\u00a0S, Fervenza\u00a0FC, Ytterberg\u00a0SR et\u00a0al (2016) Diffuse alveolar hemorrhage secondary to antineutrophil cytoplasmic antibody-associated vasculitis: predictors of respiratory failure and clinical outcomes. Arthritis Rheumatol 68(6):1467\u20131476","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"1548_CR22","doi-asserted-by":"publisher","first-page":"e0196009","DOI":"10.1371\/journal.pone.0196009","volume":"13","author":"E Uechi","year":"2018","unstructured":"Uechi\u00a0E, Okada\u00a0M, Fushimi\u00a0K (2018) Effect of plasma exchange on in-hospital mortality in patients with pulmonary hemorrhage secondary to antineutrophil cytoplasmic antibody-associated vasculitis: A\u00a0propensity-matched analysis using a\u00a0nationwide administrative database. PLoS ONE 13(4):e196009","journal-title":"PLoS ONE"},{"issue":"21","key":"1548_CR23","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1001\/jama.2010.1658","volume":"304","author":"TF Hiemstra","year":"2010","unstructured":"Hiemstra\u00a0TF, Walsh\u00a0M, Mahr\u00a0A, Savage\u00a0CO, de Groot\u00a0K, Harper\u00a0L et\u00a0al (2010) Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a\u00a0randomized controlled trial. JAMA 304(21):2381\u20132388","journal-title":"JAMA"},{"issue":"19","key":"1548_CR24","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","volume":"371","author":"L Guillevin","year":"2014","unstructured":"Guillevin\u00a0L, Pagnoux\u00a0C, Karras\u00a0A, Khouatra\u00a0C, Aumaitre\u00a0O, Cohen\u00a0P et\u00a0al (2014) Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N\u00a0Engl J Med 371(19):1771\u20131780","journal-title":"N Engl J Med"},{"key":"1548_CR25","doi-asserted-by":"crossref","unstructured":"Smith\u00a0RM, Jones\u00a0RB, Specks\u00a0U, Bond\u00a0S, Nodale\u00a0M, Al-Jayyousi\u00a0R et al (2023) Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial. Ann Rheum Dis 82(7):937\u2013944","DOI":"10.1136\/ard-2022-223559"},{"issue":"8","key":"1548_CR26","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","volume":"77","author":"P Charles","year":"2018","unstructured":"Charles\u00a0P, Terrier\u00a0B, Perrodeau\u00a0E, Cohen\u00a0P, Faguer\u00a0S, Huart\u00a0A et\u00a0al (2018) Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a\u00a0multicentre, randomised controlled, phase\u00a0III trial (MAINRITSAN2). Ann Rheum Dis 77(8):1143\u20131149","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1548_CR27","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1136\/ard-2023-224623","volume":"83","author":"F Delestre","year":"2024","unstructured":"Delestre\u00a0F, Charles\u00a0P, Karras\u00a0A, Pagnoux\u00a0C, Neel\u00a0A, Cohen\u00a0P et\u00a0al (2024) Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials. Ann Rheum Dis 83(2):233\u2013241","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1548_CR28","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/ard-2023-224489","volume":"83","author":"R Zonozi","year":"2024","unstructured":"Zonozi\u00a0R, Cortazar\u00a0FB, Jeyabalan\u00a0A, Sauvage\u00a0G, Nithagon\u00a0P, Huizenga\u00a0NR et\u00a0al (2024) Maintenance of remission of ANCA vasculitis by rituximab based on B\u00a0cell repopulation versus serological flare: a\u00a0randomised trial. Ann Rheum Dis 83(3):351\u2013359","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1548_CR29","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1136\/annrheumdis-2022-222439","volume":"81","author":"G McDermott","year":"2022","unstructured":"McDermott\u00a0G, Fu\u00a0X, Cook\u00a0C, Ahola\u00a0C, Doliner\u00a0B, Hanberg\u00a0J et\u00a0al (2022) The effect of achieving serological remission on subsequent risk of relapse, end-stage renal disease and mortality in ANCA-associated vasculitis: a\u00a0target trial emulation study. Ann Rheum Dis 81(10):1438\u20131444","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1548_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2215\/CJN.06460622","volume":"18","author":"M Casal Moura","year":"2023","unstructured":"Casal Moura\u00a0M, Specks\u00a0U, Tehranian\u00a0S, Sethi\u00a0S, Zubidat\u00a0D, Nardelli\u00a0L et\u00a0al (2023) Maintenance of remission and risk of relapse in myeloperoxidase-positive ANCA-associated vasculitis with kidney involvement. Clin J Am Soc Nephrol 18(1):47\u201359","journal-title":"Clin J Am Soc Nephrol"},{"issue":"20","key":"1548_CR31","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","volume":"376","author":"ME Wechsler","year":"2017","unstructured":"Wechsler\u00a0ME, Akuthota\u00a0P, Jayne\u00a0D, Khoury\u00a0P, Klion\u00a0A, Langford\u00a0CA et\u00a0al (2017) Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N\u00a0Engl J Med 376(20):1921\u20131932","journal-title":"N Engl J Med"},{"issue":"10","key":"1548_CR32","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa2311155","volume":"390","author":"ME Wechsler","year":"2024","unstructured":"Wechsler\u00a0ME, Nair\u00a0P, Terrier\u00a0B, Walz\u00a0B, Bourdin\u00a0A, Jayne\u00a0DRW et\u00a0al (2024) Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis. N\u00a0Engl J Med 390(10):911\u2013921","journal-title":"N Engl J Med"},{"issue":"8","key":"1548_CR33","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/art.41773","volume":"73","author":"SA Chung","year":"2021","unstructured":"Chung\u00a0SA, Langford\u00a0CA, Maz\u00a0M, Abril\u00a0A, Gorelik\u00a0M, Guyatt\u00a0G et\u00a0al (2021) 2021 American college of rheumatology\/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol 73(8):1366\u20131383","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"1548_CR34","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41584-023-00958-w","volume":"19","author":"G Emmi","year":"2023","unstructured":"Emmi\u00a0G, Bettiol\u00a0A, Gelain\u00a0E, Bajema\u00a0IM, Berti\u00a0A, Burns\u00a0S et\u00a0al (2023) Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis. Nat Rev Rheumatol 19(6):378\u2013393","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"1548_CR35","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/acr.23912","volume":"72","author":"R Solans-Laque","year":"2020","unstructured":"Solans-Laque\u00a0R, Rodriguez-Carballeira\u00a0M, Rios-Blanco\u00a0JJ, Fraile\u00a0G, Saez-Comet\u00a0L, Martinez-Zapico\u00a0A et\u00a0al (2020) Comparison of the birmingham vasculitis activity score and the five-factor score to assess survival in antineutrophil cytoplasmic antibody-associated vasculitis: a\u00a0study of 550 patients from spain (REVAS registry). Arthritis Care Res 72(7):1001\u20131010","journal-title":"Arthritis Care Res"},{"issue":"1","key":"1548_CR36","doi-asserted-by":"publisher","first-page":"e000905","DOI":"10.1136\/rmdopen-2019-000905","volume":"5","author":"V Teixeira","year":"2019","unstructured":"Teixeira\u00a0V, Mohammad\u00a0AJ, Jones\u00a0RB, Smith\u00a0R, Jayne\u00a0D (2019) Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. RMD Open 5(1):e905","journal-title":"RMD Open"},{"issue":"2","key":"1548_CR37","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/art.23198","volume":"58","author":"C Ribi","year":"2008","unstructured":"Ribi\u00a0C, Cohen\u00a0P, Pagnoux\u00a0C, Mahr\u00a0A, Arene\u00a0JP, Lauque\u00a0D et\u00a0al (2008) Treatment of Churg-Strauss syndrome without poor-prognosis factors: a\u00a0multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum 58(2):586\u2013594","journal-title":"Arthritis Rheum"},{"issue":"11","key":"1548_CR38","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1002\/art.40205","volume":"69","author":"X Puechal","year":"2017","unstructured":"Puechal\u00a0X, Pagnoux\u00a0C, Baron\u00a0G, Quemeneur\u00a0T, Neel\u00a0A, Agard\u00a0C et\u00a0al (2017) Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg-Strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors: a\u00a0randomized, controlled trial. Arthritis Rheumatol 69(11):2175\u20132186","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"1548_CR39","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/art.41943","volume":"74","author":"A Bettiol","year":"2022","unstructured":"Bettiol\u00a0A, Urban\u00a0ML, Dagna\u00a0L, Cottin\u00a0V, Franceschini\u00a0F, Del Giacco\u00a0S et\u00a0al (2022) Mepolizumab for eosinophilic granulomatosis with polyangiitis: a\u00a0european multicenter observational study. Arthritis Rheumatol 74(2):295\u2013306","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"1548_CR40","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1136\/annrheumdis-2012-201531","volume":"72","author":"F Moosig","year":"2013","unstructured":"Moosig\u00a0F, Bremer\u00a0JP, Hellmich\u00a0B, Holle\u00a0JU, Holl-Ulrich\u00a0K, Laudien\u00a0M et\u00a0al (2013) A\u00a0vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis 72(6):1011\u20131017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1548_CR41","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/acr2.11263","volume":"3","author":"I Doubelt","year":"2021","unstructured":"Doubelt\u00a0I, Cuthbertson\u00a0D, Carette\u00a0S, Chung\u00a0SA, Forbess\u00a0LJ, Khalidi\u00a0NA et\u00a0al (2021) Clinical manifestations and long-term outcomes of eosinophilic granulomatosis with polyangiitis in North America. ACR Open Rheumatol 3(6):404\u2013412","journal-title":"ACR Open Rheumatol"},{"issue":"6","key":"1548_CR42","first-page":"952","volume":"77","author":"G Emmi","year":"2018","unstructured":"Emmi\u00a0G, Rossi\u00a0GM, Urban\u00a0ML, Silvestri\u00a0E, Prisco\u00a0D, Goldoni\u00a0M et\u00a0al (2018) Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis 77(6):952\u2013954","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1548_CR43","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1136\/annrheumdis-2014-206095","volume":"75","author":"AJ Mohammad","year":"2016","unstructured":"Mohammad\u00a0AJ, Hot\u00a0A, Arndt\u00a0F, Moosig\u00a0F, Guerry\u00a0MJ, Amudala\u00a0N et\u00a0al (2016) Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis 75(2):396\u2013401","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1548_CR44","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1136\/ard-2023-224756","volume":"82","author":"B Molina","year":"2023","unstructured":"Molina\u00a0B, Padoan\u00a0R, Urban\u00a0ML, Novikov\u00a0P, Caminati\u00a0M, Taille\u00a0C et\u00a0al (2023) Dupilumab for relapsing or refractory sinonasal and\/or asthma manifestations in eosinophilic granulomatosis with polyangiitis: a\u00a0European retrospective study. Ann Rheum Dis 82(12):1587\u20131593","journal-title":"Ann Rheum Dis"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01548-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-024-01548-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01548-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T08:04:25Z","timestamp":1733213065000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-024-01548-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,28]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1548"],"URL":"https:\/\/doi.org\/10.1007\/s00393-024-01548-1","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,28]]},"assertion":[{"value":"19 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.U.\u00a0Holle und F.\u00a0Moosig geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}